Published in final edited form as:

Nature. 2014 May 15; 509(7500): 310–317. doi:10.1038/nature13085.

Nucleotide signalling during inflammation

Marco Idzko¹, Davide Ferrari², and Holger K. Eltzschig³

¹Department of Pneumology, Freiburg University Medical Center, Albert-Ludwigs-University, 79106 Freiburg, Germany

²Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, University of Ferrara, Ferrara, 44121, Italy

³Organ Protection Program, Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA

Abstract

Inflammatory conditions are associated with the extracellular release of nucleotides, particularly ATP. In the extracellular compartment, ATP predominantly functions as a signalling molecule through the activation of purinergic P2 receptors. Metabotropic P2Y receptors are G-protein-coupled, whereas ionotropic P2X receptors are ATP-gated ion channels. Here we discuss how signalling events through P2 receptors alter the outcomes of inflammatory or infectious diseases. Recent studies implicate a role for P2X/P2Y signalling in mounting appropriate inflammatory responses critical for host defence against invading pathogens or tumours. Conversely, P2X/P2Y signalling can promote chronic inflammation during ischaemia and reperfusion injury, inflammatory bowel disease or acute and chronic diseases of the lungs. Although nucleotide signalling has been used clinically in patients before, research indicates an expanding field of opportunities for specifically targeting individual P2 receptors for the treatment of inflammatory or infectious diseases.

Nucleotides—particularly ATP—are well known for their function as a universal energy currency¹. Interestingly, ATP has a completely different role in the extracellular compartment, where it functions as a signalling molecule through the activation of nucleotide receptors¹. These receptors are referred to as purinergic P2 receptors. In contrast to P1 receptors, which are activated by the ATP metabolite adenosine, P2 receptors are activated by ATP and/or other nucleotides (for example, UTP). On the basis of their signalling properties, P2 receptors can be further subdivided into metabotropic P2Y receptors (P2YRs) that are G-protein-coupled, and ionotropic P2X receptors (P2XRs) that are nucleotide-gated ion channels². Although P2 receptors were originally described on the basis of their functional role in the central nervous system^{3,4}, more recent studies

©2014 Macmillan Publishers Limited. All rights reserved

Correspondence and requests for materials should be addressed to M.I. (marco.idzko@uniklinik-freiburg.de).

Author Contributions M.I., D.F. and H.K.E. all contributed to the writing of this paper.

Reprints and permissions information is available at www.nature.com/reprints.

The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper.

Supplementary Information is available in the online version of the paper.

demonstrate their widespread expression throughout different tissues (Supplementary Table 1) and implicate them in innate or adaptive immune responses^{2,5}.

Cellular ATP release during inflammatory conditions

During certain conditions—for example inflammatory, ischaemic and hypoxic—several cell types release ATP from intracellular storage pools into the extracellular compartment^{2,5,6}. Although ATP release can occur in an uncontrolled fashion (for example, during necrosis), many studies have examined molecular pathways that control extracellular ATP release⁵. For example, inflammatory cells can release ATP via pannexins or connexin hemichannels^{2,7}. Pannexins—transmembrane protein channels that connect the intracellular with the extracellular space—have been implicated in the release of ATP from apoptotic cells⁸, and other studies have implicated connexins in extracellular nucleotide release^{6,7}. Connexins were originally described as gap junction proteins consisting of two hemichannels. However, isolated hemichannels (connexons) can function as conduits between the cytoplasm and the extracellular space, thereby controlling ATP release, for example from inflammatory cells⁷ or vascular endothelia⁹. Other studies found that the release of uridine nucleotides such as UTP, UDP and UDP-glucose are increased during cystic fibrosis¹⁰. Together, these studies indicate that inflammatory disease conditions are associated with the extracellular release of nucleotides.

Molecular structure and signalling cascade of P2YR

P2YR belongs to the G-protein-coupled receptor (GPCR) family and contains an extracellular amino terminus, an intracellular carboxy terminus and seven transmembrane-spanning motifs (Fig. 1). At present, eight distinct mammalian P2YRs have been cloned and characterized (P2Y_{1/2/4/6/11/12/13/14}R). The missing numbers represent either non-mammalian receptors (P2Y₃R is the chicken orthologue of human P2Y₆R) or other GPCRs that share some sequence homology with P2YRs but cannot be activated by nucleotides (for example, lysophosphatidic acid is a P2Y₉R agonist)¹¹. According to their phylogenetic and sequence divergence, two distinct P2YR subgroups have been proposed. The first group includes the P2Y_{1/2/4/6/11}R subtypes, with a sequence homology of 35–52% in amino acid composition and the presence of a Y-Q/K-X-X-R defining motif in the transmembrane α -helix 7, thus affecting ligand-binding characteristics. The second group contains P2Y_{12/13/14}R, with members sharing a sequence homology of 47–48% and the presence of the K-E-X-X-L motif in transmembrane α -helix 7 (ref. 11). There is some evidence suggesting that the two P2YR subgroups also differ in their primary coupling to G proteins: the P2Y_{1/2/4/6/11}R group is coupled to G_q/G₁₁ (leading to calcium release via phospholipase C/inositol-1,4,5-triphosphate activation). By contrast, P2Y_{12/13/14}R bind to G_{i/o} proteins, which inhibit adenylate cyclase and modulate flow through ion channels^{11,12}. However, there are several instances in which other signalling pathways have been identified. For example, the discrepancy between structural-group affiliation and functional characteristics is highlighted by P2Y₁₂R. Despite having only 20–25% sequence homology with P2Y_{1/2/4/6}R¹², there is considerable functional similarity. Indeed, P2Y₁₂ and P2Y₂R can both activate monomeric G-proteins (such as Rac and/or RhoA)¹³, and are the only P2YR subtypes that exhibit agonist-induced desensitization through GPCR kinases¹⁴. These

studies indicate that despite some sequence homology among P2YRs, there are marked differences between individual members of the P2YR family regarding their intracellular signalling cascades.

Endogenous ligands for P2YR

The most abundant and best-characterized endogenous ligand for P2YR is the nucleotide ATP. ATP binds to all P2YRs except P2Y₆R and P2Y₁₄R¹². Its binding characteristics exemplify the complexity of P2YR signalling: at low concentrations it is the only native agonist for P2Y₁₁R, but at higher concentrations it functions as a partial agonist for P2Y₁R and P2Y₁₃R, or as an antagonist for human P2Y₄R or P2Y₁₂R^{11,12,15}. Other nucleotides, such as ADP, UTP, UDP or UDP-glucose, exhibit more specificity for individual P2YRs. For example, ADP activates P2Y₁R, P2Y₁₂R and P2Y₁₃R, whereas UTP primarily binds to P2Y₂R and P2Y₄R, and to a lesser extent to P2Y₆R, for which UDP is its preferred native ligand. P2Y₁₄R is predominantly activated by UDP-glucose and other UDP-sugars, and to a lesser degree by UDP^{11,12,15,16}. Indeed, the capacity of different nucleotides to bind specifically to individual P2YRs, or to act as either agonists or antagonists, highlights the complexity of the P2Y system and suggests non-redundant signalling pathways.

Pharmacological compounds that act on P2YR

Owing to the fact that P2YRs have crucial roles in regulating immune responses, they became an obvious pharmacological target for the treatment of inflammatory or infectious diseases. Interestingly the parasiticide suramin, which was widely used in the 1920s for the treatment of human onchocerciasis and trypanosomiasis^{17,18}, was later found to be a nonspecific inhibitor of P2YR and P2XR^{11,15}. Although many P2YR-subtype-specific agonists or antagonists have been characterized in *in vitro* assays or animal studies of inflammatory disorders^{11,12,15}, presently only two types of P2YR-specific compounds are used in patients: antithrombotic P2Y₁₂R antagonists (for example, clopidogrel) and the P2Y₂R agonist denufisol, which was examined for the treatment of cystic fibrosis, but eventually failed in clinical trials¹⁹. One of the important future challenges for targeting P2YR signalling in patients will include the development of highly selective P2YR antagonists, or specific combined P2R antagonists (for example, a P2Y₂/P2Y₆/P2X₇R antagonist), which could be used for the treatment of chronic inflammatory disorders.

Functional roles of P2YR in unchallenged mice

Mice with genetic deletions for human P2YR homologous genes have been generated and characterized, with the exception of *P2RY11*, which is not expressed in mice¹². Despite their widespread expression and their functional involvement in many diseases, mice with global deletions for individual P2YRs display only mild phenotypical alterations when maintained unchallenged in a germ-free environment. For instance, *P2ry2*^{-/-} mice have slightly lower plasma concentrations of aldosterone, renin and potassium²⁰, whereas global deletion of *P2ry4* is associated with lower exercise capacity and reduced myocardial hypertrophy during a swimming exercise²¹. These findings indicate the likelihood of some redundancy in the signalling system, or compensatory mechanisms following global *P2ry* gene deletion.

P2Y₂R signalling during inflammatory disease states

Several studies over the past decade have highlighted fundamental roles for P2Y₂R during inflammatory and infectious diseases. Particularly, signalling events through P2Y_{2/6/12}R have shaped an ambivalent view of their function as either friend or foe during inflammation.

P2Y₂R

An early attempt at targeting P2Y signalling for the treatment of inflammatory disorders came from studies of P2Y₂R agonists for the treatment of cystic fibrosis^{22,23}. Cystic fibrosis is a life-shortening disease that affects over 30,000 children and adults in the United States²⁴. The airways of patients with cystic fibrosis are susceptible to infection, characterized by neutrophilic inflammation. Although neutrophil proteases are critical for killing engulfed bacteria, neutrophil elastase accumulates in the airways of cystic fibrosis patients, impairing ciliary function, crippling bacterial clearance and degrading structural proteins²⁴. From a molecular perspective, cystic fibrosis is characterized by a defect in the cystic fibrosis transmembrane conductance regulator gene, causing hyperabsorption of sodium leading to thickening of mucus, reduced mucociliary clearance and concomitant increases in susceptibility to bacterial infection^{22,23}. Several studies have indicated that P2Y₂R agonists can induce chloride secretion through inhibition of the epithelial sodium channel ENaC, activation of calcium-dependent chloride channels²⁵, stimulation of mucin production, surfactant secretion and ciliary beating (Fig. 2)²⁵. These observations were followed by the development of the P2Y₂R agonist denufosal for the treatment of patients suffering from cystic fibrosis²⁶. In 2005 denufosal entered clinical trials, and a 28-day intervention study in a small cohort indicated a potential benefit in lung function of cystic fibrosis patients²⁷. Unfortunately, long-term follow-up (48 weeks) in 466 patients was not associated with improved pulmonary function or reduction of pulmonary exacerbations¹⁹. These disappointing findings may be related to an inflammatory role for P2Y₂R signalling (see below)².

In addition to a means for enhancing mucociliary clearance, P2Y₂R agonists have been implicated in the promotion of wound healing²⁸. In this context, P2Y₂R signalling mediates the recruitment of leukocytes to the site of tissue damage as well as differentiation and proliferation of structural cells. Moreover, ATP release and concomitant P2Y₂R signalling has been identified as a 'find-me' signal for leukocytes, promoting phagocytic clearance of apoptotic cells or bacteria by macrophages²⁹ and neutrophils^{30,31}, thereby contributing to the resolution of inflammation (Fig. 2).

Other studies have indicated that P2Y₂R signalling contributes to fundamental leukocyte functions such as migration and mediator production by neutrophils, eosinophils, dendritic cells (DCs) and macrophages^{32,33}. For example, migrating neutrophils can release ATP from their leading edge to amplify chemotactic signals and direct cell orientation by feedback signalling involving P2Y₂R (Fig. 2)³¹. In addition, danger signals such as uric acid, complement factor 5a, Toll-like receptor ligands and interleukin (IL)-8 are stimulated by an autocrine ATP–P2Y₂R loop to modulate migration and cytokine production of neutrophils or eosinophils^{2,31,34–36}. Several studies point towards an ambivalent function of

P2Y₂R in neutrophilic inflammation: although *P2ry2*^{-/-} mice are less capable of containing bacterial infections^{30,37}, inappropriate activation of P2Y₂R is associated with neutrophil-induced hyperinflammation and tissue damage during sepsis, chronic lung disease and hepatitis (Fig. 2)^{38–41}. For example, neutrophils from patients with chronic obstructive pulmonary disease express higher levels of P2Y₂R, which is associated with higher elastolytic activity and migration capacity upon ATP stimulation compared to healthy controls⁴⁰. In the context of P2Y₂R agonists for the treatment of cystic fibrosis, these findings could explain why the long-term use of inhaled denufosol in cystic fibrosis patients failed to improve clinical outcomes, as it may have been associated with enhanced neutrophil activation and increased lung inflammation, thus overcoming the beneficial effects of improved mucociliary clearance.

Studies in murine models of asthma or contact hypersensitivity demonstrate a contribution of P2Y₂R to the induction and self-perpetuation of allergic diseases. Allergen provocation leads to ATP release and concomitant signalling through P2Y₂R, thus favouring the recruitment of immature myeloid DCs and eosinophils to the site of allergen exposures^{42–44}. This is associated with the production of pro-allergic mediators (for example, IL-33, IL-8, eosinophil cationic protein) from different cellular sources (Fig. 2)^{33,45,46}. Similarly, studies in humans indicate that P2Y₂R-induced migration and production of reactive oxygen species are enhanced in immature monocyte-derived DCs and eosinophils from allergic donors in the context of concomitant increases in P2Y₂R expression⁴³.

Taken together, these findings suggest that ATP-elicited activation of P2Y₂R can function as a ‘friend’ in the defence against bacterial infections, promotion of wound healing or in enhancement of mucociliary clearance mechanisms. By contrast, it can also lead to uncontrolled inflammation, attenuated resolution, promotion of chronic inflammatory disease states and fibrotic remodelling⁴⁷. Indeed, P2Y₂R antagonists—as opposed to P2Y₂R agonists—could evolve as useful drugs for the treatment for chronic inflammatory diseases, such as chronic obstructive pulmonary disease (Fig. 2)^{40,41}.

P2Y₆R

P2Y₆R is highly expressed on stromal cells and can be activated by UDP^{48–50}. The ambivalent behaviour (‘friend or foe’) of P2Y₂R signalling during inflammatory diseases also applies to P2Y₆R signalling. Recent *in vivo* studies demonstrate a role of P2Y₆R in innate immune responses against bacterial infection⁵¹. P2Y₆R activation triggers chemokine release from monocytes, DCs, eosinophils and endothelial cells, thus promoting recruitment of inflammatory cells towards the site of inflammation or infection^{11,48,51–53}. Similarly, one study demonstrated that injured neurons release UTP and UDP, causing the upregulation of P2Y₆R expression on microglia, and concomitant enhancement of their phagocytic capacity for dying cells⁵⁴. UDP signalling through P2Y₆R can therefore function as an ‘eat-me’ signal for microglia, thereby initiating the clearance of dying cells or debris in the central nervous system.

By contrast, P2Y₆R signalling is detrimental in models of endothelial⁵⁰ or epithelial⁴⁹ inflammation. Mucosal P2Y₆R expression is increased during experimentally induced intestinal inflammation such as occurs during inflammatory bowel disease (IBD)⁴⁹. IBD is a

heterogeneous group of disorders characterized by intestinal inflammation, including Crohn's disease and ulcerative colitis. Here, pharmacological inhibition or genetic deletion of *P2ry6* in murine models of intestinal inflammation is associated with improved disease outcomes⁵⁵. Similarly, a functional role for P2Y₆R signalling in promoting detrimental inflammation has been reported for chronic forms of lung disease, such as asthma⁴⁸. Indeed, its functional role in promoting pathological airway inflammation during chronic lung disease is an important concern regarding potential considerations for the use of P2Y₆R agonists for the treatment of cystic fibrosis as a means towards enhancing mucociliary clearance²⁵. The idea that UDP-elicited P2Y₆R activation can lead to self-perpetuating chronic inflammatory disorders is further supported by recent *in vivo* findings suggesting a functional role of P2Y₆R in promoting atherosclerotic disease in murine models⁵⁶. Taken together, these studies indicate that although activation of P2Y₆R is important in initiating innate immune responses after infection, inappropriate P2Y₆R signalling, predominantly on stromal cells, can drive detrimental immune responses in chronic inflammatory disorders such as atherosclerosis, chronic lung disease or IBD.

P2Y₁₂R

P2Y₁₂R, which is highly expressed on platelets, has fundamental roles in platelet activation and aggregation. Stimulation of P2Y₁₂R inhibits adenylyl cyclase activity and increases phosphatidylinositol-3 kinase activity, resulting in the activation of the fibrinogen receptor (integrin α IIb β 3), which is critical for platelet aggregation⁵. P2Y₁₂R antagonists have been used successfully for antithrombotic therapy in patients⁵. Because platelets are a key source of inflammatory mediators, P2Y₁₂R signalling has also been implicated in modulating inflammatory responses⁵⁷. The fact that P2Y₁₂R agonists trigger mediator release from platelets implicates inflammatory alternations in patients taking P2Y₁₂R antagonists. Importantly, P2Y₁₂R antagonists such as clopidogrel or ticagrelor are clinically used in patients as platelet inhibitors. Indeed, reduced levels of circulating inflammatory mediators (for example, tumour-necrosis factor- α , C-reactive protein, P-selectin) were found in patients receiving clopidogrel⁵⁸. Preclinical studies confirm the proinflammatory role of P2Y₁₂R signalling in models of vascular inflammation and asthma. For instance *P2ry12*^{-/-} mice are protected in models of atherosclerosis^{59,60}. Moreover, a surprising crosstalk involving leukotrienes and P2Y₁₂R has been described during asthma. In brief, murine studies demonstrate that P2Y₁₂R signalling on platelets is required for the pro-asthmatic action of leukotriene LTE₄ (ref. 61). Furthermore, platelet-independent P2Y₁₂R signalling events contribute to asthma, as P2Y₁₂R antagonists can directly block cysteinyl leukotriene-induced release of eosinophil cationic protein from human eosinophils⁶², and ADP-elicited P2Y₁₂R activation enhances the capacity of DCs to activate allergen-specific T cells⁶³. The clinical observation that single nucleotide polymorphisms of the *P2RY12* gene are associated with altered lung function in a cohort of asthmatic children provides additional evidence for a role of P2Y₁₂R signalling in human asthma⁶⁴. Taken together, these studies implicate P2Y₁₂R signalling in promoting chronic inflammatory disorders such as asthma and atherosclerosis. However, additional clinical trials addressing the clinical efficacy of P2Y₁₂R antagonists (such as clopidogrel or ticagrelor) for the treatment or prevention of chronic inflammation will be critical in establishing their clinical usefulness beyond current indications.

P2XR signalling during inflammation

Molecular structure and signalling cascade of P2XR

P2XRs are plasma membrane channels selective for monovalent and divalent cations (Na^+ , K^+ , Ca^{2+}) which are directly activated by extracellular ATP (Fig. 1)⁶⁵. Seven different subunits have been identified so far (P2X₁₋₇R)⁶⁵. The primary sequence of P2XRs has no important sequence homology with other ligand-gated ion channels, ATP-binding proteins or other known proteins⁶⁶. P2XRs share a common topology with two transmembrane domains (TM1 and TM2), a large extracellular loop responsible for ligand binding, and an intracellular N and a longer C terminus⁶⁷. The extracellular 'loop' starts in proximity of position 52, and ends near proline 329, therefore most of the P2XR protein protrudes from the plasma membrane. Evidence suggests that functional P2XRs are trimers, with three peptide subunits arranged around an ion-permeable channel pore, where ATP binding promotes subunit rearrangement and ion channel opening⁶⁸. Three molecules of ATP seem to bind to the extracellular portions of P2XR⁶⁷. Channel opening induces transmembrane ion fluxes, that is, Na^+ and Ca^{2+} influx and K^+ efflux, leading to plasma membrane depolarization, and—due to the increase of intracellular Ca^{2+} levels—activation of Ca^{2+} signalling cascades, such as p38 MAPK or phospholipase A₂ activation⁶⁷. Interestingly, P2X₇R is capable of activating the NOD-like-receptor-mediated inflammasome assembly with pro-caspase 1 proteolytic activation and subsequent pro-IL-1 and pro-IL-18 cleavage and release of their biologically active forms⁶⁵. The long C-terminal 'tail' of P2X₇R allows it to undergo a conformational change resulting in the so called 'permeability transition'; that is, P2X₇R changes from a cationic channel to a wider pore, allowing transmembrane fluxes of small hydrophilic molecules (including ATP) with a molecular mass of approximately 900 (refs 69, 70).

In addition, some P2XRs, for example P2X₁R, can form heterotrimers with P2X₂R, P2X₄R and P2X₅R subunits, whereas P2X₂R forms heterooligomers with P2X₃R⁶⁶. Together these findings indicate that despite the fact that all P2XRs are activated by ATP and share significant sequence homology with each other, highly distinct functions are unique for individual members of the P2XR family.

Endogenous and pharmacological ligands for P2XR

In contrast to P2YR signalling, for which more than one native agonist exists, human P2XRs share ATP as their main endogenous agonist⁷¹. Owing to the central role of P2X₇R during inflammatory disorders, great efforts have been made to develop selective antagonists. For example, the P2X₇R antagonist AZ9056 was used in patients with rheumatoid arthritis. Although initial studies were promising, Phase IIb/III studies with different P2X₇R antagonists failed to improve long-term clinical outcomes⁷². In addition, there are ongoing Phase II studies with P2X₇R and P2X₃R antagonists in chronic pain and chronic cough (<http://www.clinicaltrials.gov>)⁷², highlighting the potential for P2XRs as drugable targets in the treatment of inflammatory disorders.

Functional roles of P2XR in unchallenged mice

Physiological roles of P2XRs are indicated by phenotypic manifestations in mice lacking individual P2XR subtypes. Although all single *P2rx* knockout mice are viable and survive to adulthood, some of them reveal unexpected phenotypes, suggesting that functional roles of individual receptor subunits cannot be compensated for by others. For instance, *P2rx1*^{-/-} mice show reduced vas deferens contraction and are infertile⁷³, whereas *P2rx2*^{-/-} mice develop severe progressive hearing loss⁷⁴, and *P2rx3*^{-/-} mice experience urinary bladder hyporeflexia⁷⁵. Mice lacking both *P2rx2* and *P2rx3* have enlarged spleens and increased numbers of immune cells⁷⁶. These findings suggest P2XR-subtype-specific signalling functions under physiological conditions, including immune functions.

P2X₇R signalling during inflammatory disease

Compelling evidence implicates P2XR during inflammation and immune response against microbes^{72,78}. Although several other P2XRs are functional during inflammation (for example, P2X₄R), P2X₇R in particular has been shown to affect the outcomes of inflammatory or infectious diseases. This may be due to the fact that P2X₇R is predominantly expressed on immune cells such as mast cells, macrophages, microglia and DCs (s)². Indeed, functional studies implicate P2X₇R in immune responses against bacterial and parasitic infection. For example, activation of P2X₇R is involved in the formation of macrophage multinucleated giant cells, an important step for the control of tuberculosis (Fig. 3)⁷⁷. Other studies implicate P2X₇R signalling in the elimination of intracellular microbes—such as *Mycobacterium tuberculosis*, *Chlamydia psittaci*, *Leishmania amazonensis* or *Toxoplasma gondii*—by either killing of the pathogen or by inducing cell death of infected macrophages (Fig. 3)⁷⁸. Human studies indicate that loss-of-function mutations in the *P2RX7* gene are associated with increased susceptibility to tuberculosis or toxoplasmosis⁷⁸. Owing to its proinflammatory role via activation of the inflammasome, and its direct cytotoxic or pro-apoptotic function, many reports implicate a role for the ATP–P2X₇R axis in tumour suppression. P2X₇R expression is lower in some types of cancer and loss-of-function mutations in the *P2RX7* gene have been linked to the pathogenesis of chronic lymphatic leukaemia⁷⁹. Additional evidence comes from studies demonstrating that loss-of-function mutations of the *P2RX7* gene in patients with breast cancer are associated with an increased risk of progression to metastatic disease states⁸⁰. This study specifically implicated DC–P2X₇R signalling in resistance to chemotherapy (Fig. 3). DCs present antigens from dying cancer cells to prime tumour-specific interferon- γ (IFN- γ)-producing T cells. Dying tumour cells release ATP, which activates P2X₇R expressed on DCs, which in turn causes inflammasome assembly and subsequent secretion of IL-1 β (Fig. 3). Accordingly, anticancer chemotherapy was shown to be inefficient against tumours established in purinergic receptor *P2rx7*^{-/-} hosts⁸⁰. Together, such findings implicate ATP signalling through the P2X₇R in host-defence mechanisms against intracellular pathogens and cancers.

It is particularly interesting that P2X₇R signalling on DCs can have very different effects on T-cell priming, depending on the specific context, including CD8⁺ and CD4⁺ T-cell differentiation (Fig. 3). In contrast to its essential role in immune priming for response against tumours or pathogens, the involvement of P2X₇R in the polarization of antigen-

specific effector T cells by DCs contributes to the induction and maintenance of chronic inflammation. P2X₇R signalling on DCs is involved in the sensitization phase of allergic disorders such as contact hypersensitivity (CD8⁺ T-cell priming)⁴⁴ and asthma (CD4⁺ T-cells, T_H2 response)⁸¹, and contributes to transplant rejection (CD4⁺ T cells, T_H1 response; Fig. 3). For example, recent studies implicate P2X₇R signalling in graft-versus-host disease, a common complication following an allogeneic tissue transplant, in which immune cells in the tissue recognize the recipient as 'foreign', leading to an immunological reaction of transplanted immune cells against the host. Indeed, P2X₇R inhibition or deficiency on DCs is associated with reduced severity of graft-versus-host disease⁸². As such, P2X₇R signalling of antigen-presenting DCs led to an increased expression of CD80 and CD86 *in vitro* and *in vivo* and activated a cascade of proinflammatory events, including signal transducer and activator of transcription 1 (STAT1) phosphorylation, IFN- γ production and donor T-cell expansion⁸². Again, other studies report that P2X₇R-mediated priming can contribute to T_H17-driven autoimmune diseases, such as psoriasis (Fig. 3)⁸³. By triggering the production of pro-allergic mediators from eosinophils, mast cells, macrophages and DCs, P2X₇R signalling also contributes to the effector phase and chronification of allergic disorders^{42,81}. Furthermore, increased expression of P2X₇R can be found on eosinophils and macrophages in asthma (Fig. 3)⁸¹, and loss-of-function mutations in the *P2rx7* gene have been associated with attenuated risk of allergen sensitization and asthma⁸⁴.

In line with these findings, other studies report a detrimental role of P2X₇R in promoting excessive inflammation during IBD, by showing that ATP derived from commensal bacteria activates a unique subset of lamina propria cells (CD70^{high} CD11c^{low} cells), leading to T_H17 cell differentiation (Fig. 3)⁸⁵. Indeed, germ-free mice exhibit lower concentrations of luminal ATP, accompanied by fewer lamina propria T_H17 cells⁸⁵. P2X₇R also participates in IBD pathogenesis by mediating enteric neural death (Fig. 3)^{85,86}. Finally, mast-cell-dependent mechanisms of intestinal inflammation are under the control of P2X₇R, as increased P2X₇R expression can be found in mast cells from Crohn's patients and inhibition of P2X₇R on mast cells dampens intestinal inflammation (Fig. 3)⁸⁷.

Together, these findings expose P2X₇R signalling during inflammation as a double-edged sword: these receptors have a critical role in mediating appropriate inflammatory and immunological responses against invading pathogens or cancer cells, respectively, but contribute to chronic inflammatory disease states in a wide range of inflammatory disorders, such as chronic lung disease^{40,88}, asthma^{81,84} or IBD^{86,87}, when activated inappropriately.

Termination of ATP signalling

Termination of P2R signalling involves the conversion of ATP/ADP to adenosine within the extracellular compartment by the activity of ectonucleotidases. The four main groups of ectonucleotidases are the ectonucleoside triphosphate diphosphohydrolases (NTPDases), ecto-5'-nucleotidase (CD73), ectonucleotide pyrophosphatase/phosphodiesterases and alkaline phosphatases⁸⁹. NTPDases represent a family of ubiquitously expressed membrane-bound enzymes. The catalytic sites of plasma membrane-expressed NTPDases 1–3 and 8 are oriented towards the extracellular milieu⁹⁰. Owing to its high expression in many tissues and its ability to catalyse the conversion of ATP (and ADP) down to AMP, many studies have

found a functional role for NTPDase1 (CD39) in the termination of P2R signalling^{90,91}. Next, extracellular AMP is converted to adenosine by CD73 (Fig. 1)⁵. Therefore, termination of ATP signalling is closely linked to the generation of extracellular adenosine. In many instances, adenosine-elicited P1R signalling dampens acute inflammation and tissue injury^{92,93}, thus opposing inflammatory functions of P2Rs (Fig. 1)^{94,95}.

Consistent with a protective role for the CD39/CD73 pathway in terminating inflammatory P2R signalling, and concomitantly increasing extracellular adenosine levels and signalling events, several studies show that *Cd39*^{-/-} or *Cd73*^{-/-} mice are prone to tissue injury during inflammatory conditions such as acute lung injury or intestinal inflammation^{96,97}. For example, patients with a single nucleotide polymorphism associated with low levels of CD39 expression have increased susceptibility to Crohn's disease, suggesting that deficiency in CD39 could be associated with IBD in humans⁹⁶. Other reports suggest that CD39 exerts a protective thromboregulatory function in stroke by preventing P2R-mediated thrombosis⁹¹. Moreover, several studies implicate the CD39/CD73 pathway in the immunosuppressive roles of regulatory T cells (T_{reg}). These are a group of CD4⁺ lymphocytes that suppress T-cell responses against a variety of pathogens and control inappropriate immune activation, thus limiting collateral tissue damage but allowing pathogen persistence⁹⁸. As such, T_{reg} cells from *Cd39*^{-/-} mice demonstrate attenuated suppressive functions *in vitro* and fail to block rejection of allografts *in vivo*⁹⁹. Similarly, *Cd73*^{-/-} mice fail to resolve lung injury induced by lipopolysaccharide inhalation due to impairment of T_{reg} functions¹⁰⁰.

The ambivalence of CD39/CD73-mediated control of T_{regs} is further exemplified during infections with human immunodeficiency virus (HIV), the retrovirus known to cause AIDS in humans. HIV infections are characterized by a progressive CD4 lymphopenia in conjunction with defective HIV-specific CD8 responses that are critical for the control of viral replication⁹⁸. As such, the consequences of T_{reg} expansion, as seen during HIV infection, could have either a beneficial function by suppressing generalized T-cell activation, or could be fatal owing to attenuated HIV-specific responses and thus promoting viral persistence⁹⁸. For example, studies demonstrate that HIV-1-positive patients have an increase of T_{reg}-associated expression of CD39. These findings indicate that the CD39/CD73 pathway is involved in T_{reg} suppression in HIV infection¹⁰¹. A genetic association study demonstrated that a polymorphism in the *CD39* gene is associated with attenuated CD39 expression and slower progression to AIDS in HIV-infected patients¹⁰¹. Thus, it can be speculated that CD39⁺ T_{regs} are the most potent T_{reg} subset to inhibit HIV-specific T-cell responses. This could at least in part account for their association with disease progression. Other examples for a detrimental role of CD39-dependent ATP breakdown come from studies of autoimmune hepatitis in which natural killer T cell dysfunction in *Cd39*^{-/-} mice protects against concanavalin A-induced hepatitis. Heightened levels of apoptosis of *Cd39*^{-/-} natural killer T cells *in vivo* and *in vitro* appear to be driven by unimpeded activation of P2X₇R¹⁰². Similarly, enzymatic removal of ATP by apyrase (conversion of ATP/ADP to AMP) or ectopic CD39 expression attenuates clearance of apoptotic cells, indicating a detrimental role for CD39-dependent ATP phosphohydrolysis in dampening efficient corpse clearance via P2Y₂R signalling²⁹. Other studies demonstrate the existence

of bacterial ectotriphosphate diphosphohydrolases—similar to human CD39—which are critical for the intracellular multiplication of *Legionella pneumophila* by preventing P2R-elicited immune responses. As such, these findings implicate bacterial ectotriphosphate diphosphohydrolases in virulence¹⁰³. Together these studies exemplify an ambivalent role for the termination of P2R signalling via enzymatic phosphohydrolysis. Although this pathway is critical in preventing excessive P2R-dependent inflammation in a sterile environment¹⁰⁴, CD39 function can become detrimental for the appropriate clearance of apoptotic debris²⁹, inflammation directed against bacterial infections¹⁰³ or by generating an immunosuppressive environment, which promotes the development or progression of cancer⁵.

Functional role of P1 signalling during inflammation

Extracellular AMP generated by phosphohydrolysis of precursor nucleotides (for example, ATP or ADP) has no clearly characterized signalling function (for example, through specific AMP receptors). However, extracellular AMP serves as the metabolic substrate for the extracellular generation of adenosine via CD73 (Fig. 1)⁵. Once generated within the extracellular compartment, adenosine can function via activation of four distinct P1 receptors: ADORA1, ADORA2A, ADORA2B or ADORA3. Adenosine signalling is terminated via uptake of adenosine from the extracellular towards the intracellular compartment through equilibrative nucleoside transporters and is metabolized to inosine via adenosine deaminase¹⁰⁵, or to AMP via adenosine kinase¹⁰⁶. Several studies implicate adenosine signalling in dampening excessive inflammation⁹². For example, *Adora2a*^{-/-} mice experience increased inflammation including extensive tissue damage, more prolonged and higher levels of proinflammatory cytokines, and mortality when exposed to sub-threshold doses of inflammatory stimuli⁹³. Other studies demonstrate that ADORA2B signalling dampens excessive inflammation during acute lung injury¹⁰⁷, promotes ischaemia tolerance and improves anaerobic carbohydrate metabolism^{108,109}. Similarly, genetic deletion or pharmacological blockade of equilibrative nucleoside transporters is associated with increased adenosine levels and improved outcomes during inflammatory disease states^{110,111}. In most instances, the anti-inflammatory signalling effects of adenosine are associated with improved outcomes during inflammatory diseases such as IBD¹¹², or during sepsis induced by caecal ligation and puncture¹¹³. However, other studies indicate that the anti-inflammatory effects of adenosine signalling can be detrimental in containing an infection with live bacteria. For example, a recent study demonstrates that antagonism of P1 receptors (for example, ADORA2B) can be useful in enhancing macrophage-mediated bacterial phagocytosis and improving polymicrobial sepsis survival in mice¹¹⁴. Together, these studies highlight that P1 and P2 receptors frequently have opposing effects in biological systems, and that shifting the balance from purinergic P2YR and P2XR signalling towards adenosine-mediated P1 signalling is an important therapeutic concept in efforts to dampen pathological inflammation and promote healing⁵.

Conclusions

The field of extracellular nucleotide signalling and metabolism is a dynamic area of research with important opportunities for novel treatments for inflammatory or infectious diseases.

On the one hand, P2R signalling functions to coordinate appropriate immune responses against invading pathogens or tumours. Indeed, pharmacological approaches that amplify extracellular ATP signalling hold promise as therapies for the treatment of cancer or during uncontrolled infections with live pathogens. Such strategies could include inhibition of ATP breakdown (for example, via nucleotidase inhibitors) or treatment with P2 receptor agonists. Conversely, inadequate P2R signalling has been associated with excessive inflammation, chronification and inappropriate resolution and fibrosis in a wide range of inflammatory diseases. In this context, treatment strategies that block P2R signalling, promote extracellular conversion of ATP to adenosine and activate adenosine receptors have been implicated in the treatment of acute or chronic inflammatory diseases. We therefore anticipate that compounds targeting these pathways will be further exploited in the treatment of inflammatory conditions in human patients in the near future.

Note added in proof

Two reports appeared online regarding the atomic structure of the P2Y₁₂R while the current review was in press. The first report provides a 2.6 Å resolution crystal structure of the human P2Y₁₂R in complex with the non-nucleotide antagonist AZD1283 (ref. 115), thus providing important insights for the development of P2Y₁₂R ligands and allosteric modulators as drug candidates. The second report provides the structures of the human P2Y₁₂R in complex with a full agonist (2-methylthio-adenosine-5'-diphosphate) at a resolution of 2.5 Å, and the corresponding ATP derivative 2-methylthio-adenosine-5'-triphosphate at 3.1 Å resolution¹¹⁶. The agonist-bound P2Y₁₂R structure answers ambiguities surrounding P2Y₁₂R-agonist recognition, and suggests unexpected interactions with several residues.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge S. A. Eltzschig for help with artwork during manuscript preparation. The present research is supported by Deutsche Forschungsgemeinschaft grant ID7/3-1 ID7/4-1 and a grant by the Boehringer-Ingelheim Foundation to I.D., as well as National Institutes of Health grants R01-DK097075, R01-HL0921, R01-DK083385, R01-HL098294, POIHL114457-01 and a grant by the Crohn's and Colitis Foundation of America to H.K.E.

References

1. Khakh BS, Burnstock G. The double life of ATP. *Sci Am.* 2009; 301:84–92. [PubMed: 20058644]
2. Junger WG. Immune cell regulation by autocrine purinergic signalling. *Nature Rev Immunol.* 2011; 11:201–212. Provides a comprehensive overview of the functional roles of purinergic signalling events on cells of the adaptive and innate immune systems. [PubMed: 21331080]
3. Fredholm B, Verkhratsky A. Purines — 80 years and very much alive. *Acta Physiol.* 2010; 199:91–92.
4. Burnstock G. Purinergic signalling and disorders of the central nervous system. *Nature Rev Drug Discov.* 2008; 7:575–590. [PubMed: 18591979]
5. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. *N Engl J Med.* 2012; 367:2322–2333. [PubMed: 23234515]

6. Eltzschig HK, Macmanus CF, Colgan SP. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. *Trends Cardiovasc Med*. 2008; 18:103–107. [PubMed: 18436149]
7. Eltzschig HK, et al. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. *Circ Res*. 2006; 99:1100–1108. [PubMed: 17038639]
8. Chekeni FB, et al. Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis. *Nature*. 2010; 467:863–867. Identifies a functional role for pannexin-mediated ATP release from cells undergoing apoptosis as a ‘find-me’ signal for phagocytes. [PubMed: 20944749]
9. Faigle M, Seessle J, Zug S, El Kasmi KC, Eltzschig HK. ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. *PLoS ONE*. 2008; 3:e2801. [PubMed: 18665255]
10. Lazarowski ER. Vesicular and conductive mechanisms of nucleotide release. *Purinergic Signal*. 2012; 8:359–373. [PubMed: 22528679]
11. Abbracchio MP, et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacol Rev*. 2006; 58:281–341. [PubMed: 16968944]
12. Jacobson KA, Balasubramanian R, Deflorian F, Gao ZG. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions. *Purinergic Signal*. 2012; 8:419–436. Provides an update on the medicinal chemistry and pharmacology of the different subtypes of adenosine receptors and P2Y receptors, including recent advances in the identification and characterization of selective ligands. [PubMed: 22371149]
13. Soulet C, et al. G_i-dependent and -independent mechanisms downstream of the P2Y₁₂ ADP-receptor. *J Thromb Haemost*. 2004; 2:135–146. [PubMed: 14717977]
14. Hardy AR, et al. P2Y₁ and P2Y₁₂ receptors for ADP desensitize by distinct kinase-dependent mechanisms. *Blood*. 2005; 105:3552–3560. [PubMed: 15665114]
15. von Kugelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. *Pharmacol Ther*. 2006; 110:415–432. [PubMed: 16257449]
16. Harden TK, Sesma JI, Fricks IP, Lazarowski ER. Signalling and pharmacological properties of the P2Y receptor. *Acta Physiol*. 2010; 199:149–160.
17. Hawking F. Suramin: with special reference to onchocerciasis. *Adv Pharmacol Chemother*. 1978; 15:289–322. [PubMed: 358805]
18. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH. Recent research on the biological activity of suramin. *Pharmacol Rev*. 1993; 45:177–203. [PubMed: 8396782]
19. Ratjen F, et al. Long term effects of denufosal tetrasodium in patients with cystic fibrosis. *J Cyst Fibros*. 2012; 11:539–549. [PubMed: 22682898]
20. Rieg T, et al. Mice lacking P2Y₂ receptors have salt-resistant hypertension and facilitated renal Na⁺ and water reabsorption. *FASEB J*. 2007; 21:3717–3726. [PubMed: 17575258]
21. Horckmans M, et al. Gene deletion of P2Y₄ receptor lowers exercise capacity and reduces myocardial hypertrophy with swimming exercise. *Am J Physiol Heart Circ Physiol*. 2012; 303:H835–H843. [PubMed: 22865387]
22. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. *N Engl J Med*. 1991; 325:533–538. [PubMed: 1857389]
23. Parr CE, et al. Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. *Proc Natl Acad Sci USA*. 1994; 91:3275–3279. [PubMed: 8159738]
24. Davis SD, Ferkol T. Identifying the origins of cystic fibrosis lung disease. *N Engl J Med*. 2013; 368:2026–2028. [PubMed: 23692172]
25. Burnstock G, Brouns I, Adriaensen D, Timmermans JP. Purinergic signaling in the airways. *Pharmacol Rev*. 2012; 64:834–868. [PubMed: 22885703]
26. Kellerman D, et al. Denufosal: a review of studies with inhaled P2Y₂ agonists that led to Phase 3. *Pulm Pharmacol Ther*. 2008; 21:600–607. [PubMed: 18276176]

27. Deterding RR, et al. Phase 2 randomized safety and efficacy trial of nebulized denufosal tetrasodium in cystic fibrosis. *Am J Respir Crit Care Med.* 2007; 176:362–369. [PubMed: 17446337]
28. Gendaszewska-Darmach E, Kucharska M. Nucleotide receptors as targets in the pharmacological enhancement of dermal wound healing. *Purinergic Signal.* 2011; 7:193–206. [PubMed: 21519856]
29. Elliott MR, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. *Nature.* 2009; 461:282–286. [PubMed: 19741708]
30. Chen Y, et al. Purinergic signaling: a fundamental mechanism in neutrophil activation. *Sci Signal.* 2010; 3:ra45. [PubMed: 20530802]
31. Chen Y, et al. ATP release guides neutrophil chemotaxis via P2Y₂ and A₃ receptors. *Science.* 2006; 314:1792–1795. Shows that human neutrophils release ATP from the leading edge of the cell surface to amplify chemotactic signals and direct cell orientation by feedback through P2Y₂R as a mechanism of purinergic chemotaxis. [PubMed: 17170310]
32. Myrtek D, Idzko M. Chemotactic activity of extracellular nucleotides on human immune cells. *Purinergic Signal.* 2007; 3:5–11. [PubMed: 18404414]
33. Ferrari D, et al. Activation of human eosinophils via P2 receptors: novel findings and future perspectives. *J Leukoc Biol.* 2006; 79:7–15. [PubMed: 16244111]
34. Kronlage M, et al. Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. *Sci Signal.* 2010; 3:ra55. [PubMed: 20664064]
35. Ben Yebdri F, Kukulski F, Tremblay A, Sevigny J. Concomitant activation of P2Y₂ and P2Y₆ receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion. *Eur J Immunol.* 2009; 39:2885–2894. [PubMed: 19735076]
36. Kobayashi T, Kouzaki H, Kita H. Human eosinophils recognize endogenous danger signal crystalline uric acid and produce proinflammatory cytokines mediated by autocrine ATP. *J Immunol.* 2010; 184:6350–6358. [PubMed: 20483787]
37. Geary C, et al. Increased susceptibility of purinergic receptor-deficient mice to lung infection with *Pseudomonas aeruginosa*. *Am J Physiol Lung Cell Mol Physiol.* 2005; 289:L890–L895. [PubMed: 16024720]
38. Inoue Y, Chen Y, Hirsh MI, Yip L, Junger WG. A₃ and P2Y₂ receptors control the recruitment of neutrophils to the lungs in a mouse model of sepsis. *Shock.* 2008; 30:173–177. [PubMed: 18091570]
39. Ayata CK, et al. Purinergic P2Y₂ receptors promote neutrophil infiltration and hepatocyte death in mice with acute liver injury. *Gastroenterology.* 2012; 143:1620–1629. [PubMed: 22974709]
40. Lommatzsch M, et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2010; 181:928–934. [PubMed: 20093639]
41. Cicko S, et al. Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema. *J Immunol.* 2010; 185:688–697. [PubMed: 20519655]
42. Idzko M, et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. *Nature Med.* 2007; 13:913–919. Shows that allergen challenge causes acute accumulation of ATP in the airways of asthmatic subjects or in mice with experimentally induced asthma, and further implicates purinergic signalling as a key mediator in allergen-driven lung inflammation. [PubMed: 17632526]
43. Muller T, et al. The purinergic receptor P2Y₂ receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. *Allergy.* 2010; 65:1545–1553. [PubMed: 20880147]
44. Weber FC, et al. Lack of the purinergic receptor P2X₇ results in resistance to contact hypersensitivity. *J Exp Med.* 2010; 207:2609–2619. Identifies P2X₇R as a crucial receptor for extracellular ATP released in skin in response to contact allergens, and triggering of contact hypersensitivity. [PubMed: 21059855]
45. Idzko M, et al. Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils. *Br J Pharmacol.* 2003; 138:1244–1250. [PubMed: 12711624]
46. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. *J Immunol.* 2011; 186:4375–4387. [PubMed: 21357533]

47. Kunzli BM, et al. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. *Am J Physiol Gastrointest Liver Physiol.* 2007; 292:G223–G230. [PubMed: 16920697]
48. Vieira RP, et al. Purinergic receptor type 6 contributes to airway inflammation and remodeling in experimental allergic airway inflammation. *Am J Respir Crit Care Med.* 2011; 184:215–223. [PubMed: 21512170]
49. Grbic DM, Degagne E, Langlois C, Dupuis AA, Gendron FP. Intestinal inflammation increases the expression of the P2Y₆ receptor on epithelial cells and the release of CXC chemokine ligand 8 by UDP. *J Immunol.* 2008; 180:2659–2668. [PubMed: 18250478]
50. Riegel AK, et al. Selective induction of endothelial P2Y₆ nucleotide receptor promotes vascular inflammation. *Blood.* 2011; 117:2548–2555. [PubMed: 21173118]
51. Zhang Z, et al. P2Y₆ agonist uridine 5'-diphosphate promotes host defense against bacterial infection via monocyte chemoattractant protein-1-mediated monocytes/macrophages recruitment. *J Immunol.* 2011; 186:5376–5387. [PubMed: 21444765]
52. Idzko M, et al. Characterization of the biological activities of uridine diphosphate in human dendritic cells: influence on chemotaxis and CXCL8 release. *J Cell Physiol.* 2004; 201:286–293. [PubMed: 15334663]
53. Ferrari D, et al. P2 purinergic receptors of human eosinophils: characterization and coupling to oxygen radical production. *FEBS Lett.* 2000; 486:217–224. [PubMed: 11119707]
54. Koizumi S, et al. UDP acting at P2Y₆ receptors is a mediator of microglial phagocytosis. *Nature.* 2007; 446:1091–1095. Demonstrates that P2Y₆R is upregulated when neurons are damaged, and implicates its signalling function as a sensor for phagocytosis by sensing diffusible UDP signals, a novel pathway mediating microglial phagocytosis. [PubMed: 17410128]
55. Grbic DM, et al. P2Y₆ receptor contributes to neutrophil recruitment to inflamed intestinal mucosa by increasing CXC chemokine ligand 8 expression in an AP-1-dependent manner in epithelial cells. *Inflamm Bowel Dis.* 2012; 18:1456–1469. [PubMed: 22095787]
56. Guns PJ, Hendrickx J, Van Assche T, Fransen P, Bult H. P2Y receptors and atherosclerosis in apolipoprotein E-deficient mice. *Br J Pharmacol.* 2010; 159:326–336. [PubMed: 20050854]
57. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. *Nature Rev Immunol.* 2011; 11:264–274. [PubMed: 21436837]
58. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. *Thromb Haemost.* 2010; 103:71–82. [PubMed: 20062914]
59. Li D, et al. Roles of purinergic receptor P2Y₁₂, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol.* 2012; 32:e81–e89. [PubMed: 22628428]
60. Yashiro K, et al. Involvement of platelet activation by P2Y₁₂ receptor in the development of transplant arteriosclerosis in mice. *Transplantation.* 2009; 87:660–667. [PubMed: 19295309]
61. Paruchuri S, et al. Leukotriene E₄-induced pulmonary inflammation is mediated by the P2Y₁₂ receptor. *J Exp Med.* 2009; 206:2543–2555. [PubMed: 19822647]
62. Neves JS, Radke AL, Weller PF. Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules. *J Allergy Clin Immunol.* 2010; 125:477–482. [PubMed: 20159258]
63. Ben Addi A, Cammarata D, Conley PB, Boeynaems JM, Robaye B. Role of the P2Y₁₂ receptor in the modulation of murine dendritic cell function by ADP. *J Immunol.* 2010; 185:5900–5906. [PubMed: 20952684]
64. Bunyavanich S, Boyce JA, Raby BA, Weiss ST. Gene-by-environment effect of house dust mite on purinergic receptor P2Y₁₂ (*P2RY12*) and lung function in children with asthma. *Clin Exp Allergy.* 2012; 42:229–237. [PubMed: 22010907]
65. Surprenant A, North RA. Signaling at purinergic P2X receptors. *Annu Rev Physiol.* 2009; 71:333–359. [PubMed: 18851707]
66. Khakh BS, North RA. Neuromodulation by extracellular ATP and P2X receptors in the CNS. *Neuron.* 2012; 76:51–69. [PubMed: 23040806]
67. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. *Nature.* 2006; 442:527–532. Describes P2X signalling beyond its function in the autonomic nervous

- system, with particular focus on its key roles in afferent signalling, chronic pain and autocrine loops of endothelial and epithelial cells. [PubMed: 16885977]
68. Kawate T, Michel JC, Birdsong WT, Gouaux E. Crystal structure of the ATP-gated P2X₄ ion channel in the closed state. *Nature*. 2009; 460:592–598. Presents the crystal structure of zebrafish P2X₄R in its closed, resting state, including definition of the locations of three non-canonical, intersubunit ATP-binding sites, and evidence suggesting that ATP binding promotes subunit rearrangement and ion channel opening. [PubMed: 19641588]
 69. Alberto AV, et al. Is pannexin the pore associated with the P2X₇ receptor? *Naunyn Schmiedeberg Arch Pharmacol*. 2013; 386:775–787. [PubMed: 23657251]
 70. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P_{2Z} receptor for extracellular ATP identified as a P_{2X} receptor (P2X₇). *Science*. 1996; 272:735–738. [PubMed: 8614837]
 71. Schwarz N, et al. Alternative splicing of the N-terminal cytosolic and transmembrane domains of P2X₇ controls gating of the ion channel by ADP-ribosylation. *PLoS One*. 2012; 7:e41269. [PubMed: 22848454]
 72. North RA, Jarvis MF. P2X receptors as drug targets. *Mol Pharmacol*. 2013; 83:759–769. [PubMed: 23253448]
 73. Mulryan K, et al. Reduced vas deferens contraction and male infertility in mice lacking P2X₁ receptors. *Nature*. 2000; 403:86–89. [PubMed: 10638758]
 74. Yan D, et al. Mutation of the ATP-gated P2X₂ receptor leads to progressive hearing loss and increased susceptibility to noise. *Proc Natl Acad Sci USA*. 2013; 110:2228–2233. [PubMed: 23345450]
 75. Cockayne DA, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X₃-deficient mice. *Nature*. 2000; 407:1011–1015. [PubMed: 11069181]
 76. Coutinho-Silva R, Knight GE, Burnstock G. Impairment of the splenic immune system in P2X₂/P2X₃ knockout mice. *Immunobiology*. 2005; 209:661–668. [PubMed: 15804044]
 77. Falzoni S, et al. The purinergic P_{2Z} receptor of human macrophage cells. Characterization and possible physiological role *J Clin Invest*. 1995; 95:1207–1216.
 78. Coutinho-Silva R, Ojcius DM. Role of extracellular nucleotides in the immune response against intracellular bacteria and protozoan parasites. *Microbes Infect*. 2012; 14:1271–1277. [PubMed: 22634346]
 79. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. *Oncogene*. 2010; 29:5346–5358. [PubMed: 20661219]
 80. Ghiringhelli F, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 β -dependent adaptive immunity against tumors. *Nature Med*. 2009; 15:1170–1178. [PubMed: 19767732]
 81. Muller T, et al. A potential role for P2X₇R in allergic airway inflammation in mice and humans. *Am J Respir Cell Mol Biol*. 2011; 44:456–464. [PubMed: 20508067]
 82. Wilhelm K, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X₇R. *Nature Med*. 2010; 16:1434–1438. Reveals the relevance of ATP-induced activation of P2X₇R for graft-versus-host disease development, indicating that the physiological metabolite ATP must be recognized as an endogenous danger signal that has detrimental effects when released into the extracellular space after tissue damage through the activation of recipient antigen-presenting cells. [PubMed: 21102458]
 83. Killeen ME, Ferris L, Kupetsky EA, Falo L Jr, Mathers AR. Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. *J Immunol*. 2013; 190:4324–4336. [PubMed: 23479230]
 84. Manthei DM, et al. Protection from asthma in a high-risk birth cohort by attenuated P2X₇ function. *J Allergy Clin Immunol*. 2012; 130:496–502. [PubMed: 22743305]
 85. Atarashi K, et al. ATP drives lamina propria T_H17 cell differentiation. *Nature*. 2008; 455:808–812. [PubMed: 18716618]
 86. Gulbransen BD, et al. Activation of neuronal P2X₇ receptor-pannexin-1 mediates death of enteric neurons during colitis. *Nature Med*. 2012; 18:600–604. Provides evidence that activation of neuronal P2X₇R through pannexin 1 underlies neuron death and the subsequent development of

- abnormal gut motility in IBD, suggesting that this pathway could be targeted to ameliorate the progression of gut dysmotility during intestinal inflammation. [PubMed: 22426419]
87. Kurashima Y, et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. *Nature Commun.* 2012; 3:1034. [PubMed: 22948816]
 88. Lucattelli M, et al. P2X7 receptor signalling in the pathogenesis of smoke-induced lung inflammation and emphysema. *Am J Respir Cell Mol Biol.* 2010; 44:423–429. [PubMed: 20508069]
 89. Zimmermann H, Zebisch M, Strater N. Cellular function and molecular structure of ectonucleotidases. *Purinergic Signal.* 2012; 8:437–502. Summarizes what is known about the cellular and molecular functions of ATP-hydrolysing ectonucleotidases. [PubMed: 22555564]
 90. Kohler D, et al. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. *Circulation.* 2007; 116:1784–1794. [PubMed: 17909107]
 91. Pinsky DJ, et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. *J Clin Invest.* 2002; 109:1031–1040. [PubMed: 11956240]
 92. Fogel U, et al. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. *Sci Transl Med.* 2012; 4:146ra108. Here the authors developed a selective ADORA2A agonist that requires the presence of CD73 to become activated. This compound suppresses joint inflammation in experimental rheumatoid arthritis, while avoiding ADORA2A-mediated vasodilation.
 93. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. *Nature.* 2001; 414:916–920. First study to provide genetic evidence for a non-redundant role for the P1 adenosine receptor ADORA2A in the physiological negative feedback mechanism for limitation and termination of both tissue-specific and systemic inflammatory responses. [PubMed: 11780065]
 94. Sitkovsky MV, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. *Annu Rev Immunol.* 2004; 22:657–682. [PubMed: 15032592]
 95. Colgan SP, Eltzschig HK. Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery. *Annu Rev Physiol.* 2012; 74:153–175. [PubMed: 21942704]
 96. Friedman DJ, et al. CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. *Proc Natl Acad Sci USA.* 2009; 106:16788–16793. Provides evidence that CD39 deficiency exacerbates murine colitis and suggests that CD39 polymorphisms are associated with IBD in humans. [PubMed: 19805374]
 97. Eckle T, et al. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. *J Immunol.* 2007; 178:8127–8137. [PubMed: 17548651]
 98. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. *Blood.* 2013; 121:29–37. [PubMed: 23043072]
 99. Deaglio S, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med.* 2007; 204:1257–1265. Identifies CD39 and CD73 as surface markers of T_{regs} and implicates extracellular adenosine generation in an autocrine signalling loop critical for the suppressor functions of T_{regs}. [PubMed: 17502665]
 100. Ehrentauf H, et al. CD73⁺ regulatory T cells contribute to adenosine-mediated resolution of acute lung injury. *FASEB J.* 2013; 27:2207–2219. [PubMed: 23413361]
 101. Nikolova M, et al. CD39/adenosine pathway is involved in AIDS progression. *PLoS Pathog.* 2011; 7:e1002110. [PubMed: 21750674]
 102. Beldi G, et al. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis. *Hepatology.* 2008; 48:841–852. [PubMed: 18752325]
 103. Sansom FM, et al. A bacterial ecto-triphosphate diphosphohydrolase similar to human CD39 is essential for intracellular multiplication of *Legionella pneumophila*. *Cell Microbiol.* 2007; 9:1922–1935. [PubMed: 17388784]
 104. Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. *Nature Med.* 2011; 17:1391–1401. [PubMed: 22064429]

105. Eltzschig HK, et al. Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. *Blood*. 2006; 108:1602–1610. [PubMed: 16670267]
106. Morote-Garcia JC, Rosenberger P, Kuhlicke J, Eltzschig HK. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. *Blood*. 2008; 111:5571–5580. [PubMed: 18309031]
107. Schingnitz U, et al. Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. *J Immunol*. 2010; 184:5271–5279. [PubMed: 20348420]
108. Eltzschig HK, Bonney SK, Eckle T. Attenuating myocardial ischemia by targeting A2B adenosine receptors. *Trends Mol Med*. 2013; 19:345–354. [PubMed: 23540714]
109. Eckle T, et al. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. *Nature Med*. 2012; 18:774–782. [PubMed: 22504483]
110. Eckle T, et al. Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury. *FASEB J*. 2013; 27:3078–3089. [PubMed: 23603835]
111. Morote-Garcia JC, Rosenberger P, Nivillac NM, Coe IR, Eltzschig HK. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. *Gastroenterology*. 2009; 136:607–618. [PubMed: 19105964]
112. Frick JS, et al. Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. *J Immunol*. 2009; 182:4957–4964. [PubMed: 19342675]
113. Csoka B, et al. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. *J Immunol*. 2010; 185:542–550. [PubMed: 20505145]
114. Belikoff BG, et al. A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. *J Immunol*. 2011; 186:2444–2453. [PubMed: 21242513]
115. Zhang, K., et al. Structure of the human P2Y₁₂ receptor in complex with an antithrombotic drug. *Nature*. Mar 23. 2014 <http://dx.doi.org/10.1038/nature13083>
116. Zhang J, et al. Agonist-bound structure of the human P2Y₁₂ receptor. *Nature*. (in the press).

Figure 1. Extracellular nucleotide release and signalling during inflammation

During inflammation, multiple cell types release nucleotides, for example ATP or ADP, from their intracellular compartments into the extracellular space. Nucleotides can be released during mechanical injury, necrosis, apoptosis or inflammatory cell activation. Several molecular pathways have been implicated in this process, such as vesicular ADP release from platelets, pannexin-mediated ATP release during apoptosis, and connexin-or pannexin-mediated ATP release from inflammatory cells, such as neutrophils. Extracellular nucleotides function as signalling molecules through the activation of purinergic P2 receptors. These receptors can be grouped into metabotropic P2Y receptors (P2YRs; GPCRs with seven transmembrane-spanning motifs) or ionotropic P2X receptors (P2XRs), which are nucleotide-gated ion channels. Each P2XR is formed by three subunits (P2XR monomers), each of which consists of two transmembrane regions, TM1 and TM2. Binding of three molecules of ATP to the assembled P2X channel causes opening of a central pore. These conformational changes allow for flux of ions such as sodium (Na^+), calcium (Ca^{2+}) and potassium (K^+) across the membrane. ATP signalling is terminated by the enzymatic conversion of ATP to adenosine through the ectonucleoside triphosphate diphosphohydrolase CD39 (conversion of ATP/ADP to AMP) and the ecto-5'-nucleotidase CD73 (conversion of AMP to adenosine). Similar to ATP, adenosine (A) functions as an extracellular signalling molecule through the activation of purinergic P1 adenosine receptors.

Figure 2. P2Y₂R signalling during injury resolution and chronic inflammation

P2Y₂R signalling on phagocytes, such as macrophages, contributes to the clearance of apoptotic cells, which release the P2Y₂R agonist ATP as a 'find-me' signal. P2Y₂R-mediated clearance of apoptotic cells and debris contributes to wound healing. Activation of P2Y₂R by UTP or ATP promotes mucociliary clearance in the airways via inhibition of the epithelial sodium channel (ENaC), which is associated with concomitant increases in mucin production, surfactant-secretion and ciliary beating. Neutrophil-dependent ATP release and autocrine activation of P2Y₂R contributes to purinergic chemotaxis, thereby enhancing bacterial clearance during pneumonia. On the other hand, P2Y₂R-mediated release of IL-8 and neutrophil elastase (NE) from neutrophils contributes to the pathogenesis of chronic obstructive lung disease (COPD). ATP-elicited P2Y₂R signalling on alveolar epithelial cells or eosinophils causes production of pro-allergic mediators (for example, IL-33, IL-8, eosinophil cationic protein) during allergic airway disease. Similarly, P2Y₂R signalling on dendritic cells has a role during the induction and self-perpetuation of asthma.

Figure 3. P2X₇R signalling during infection and inflammation

P2X₇R is required for mounting an appropriate inflammatory response to defend against invading pathogens, for example during intracellular killing of *Mycobacterium tuberculosis* by macrophages. Dying tumour cells release ATP, which activates P2X₇R expressed on DCs, which in turn promotes the priming of IFN- γ -producing cytotoxic CD8⁺ T cells that kill cancer cells. On the other hand, P2X₇R signalling on DCs and concomitant T-cell priming contributes to allergic disease states, such as CD8⁺ T-cell-elicited contact dermatitis. DC-mediated T-cell priming under the control of P2X₇R signalling has also been shown to promote TH1 responses that are implicated in graft-versus-host disease, which contributes to the rejection of a transplanted organ. Similarly, P2X₇R-mediated T-cell priming towards a TH2 response promotes allergic airway disease during asthma. Priming of TH17 cells is critical during psoriasis and contributes to intestinal inflammation as occurs during IBD. P2X₇R signalling on enteric neurons or mast cells has been implicated in promoting intestinal inflammation during IBD.